Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106219 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
A Phase 1 study of Neuroblastoma, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 17
- Study locations
NCT04106219 is a Phase 1 study of Neuroblastoma that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 71 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (70% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT04106219, a Phase 1 study of Neuroblastoma, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 17
- Study locations
Study Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Topotecan
- DRUG LY3295668 Erbumine
Study Locations (17)
Other
- Institut Curie - Paris
- Universitätsklinikum Köln - Cologne
- Hospital Infantil Universitario Niño Jesús - Madrid
- Alder Hey Children's Hospital - Liverpool
California
- UCSF Medical Center at Mission Bay - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- University of Chicago - Comer Children's Hospital - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Ohio
- Cincinnati Childrens Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Childrens Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04106219
The ClinicalTrials.gov registry entry for NCT04106219 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (70% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04106219 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04106219 about?
NCT04106219 is a clinical study titled "A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma". The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
What is the current status of trial NCT04106219?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2020-06-11. Estimated completion is 2026-08.
What conditions does trial NCT04106219 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT04106219?
The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), LY3295668 Erbumine (DRUG).
Who is sponsoring clinical trial NCT04106219?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04106219 being conducted?
This trial has 17 study locations across California, Colorado, Illinois, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.